Keyword: Ascletis Pharmaceuticals
Aurobindo and Glenmark are cited by the FDA. Takeda inks IBD discovery pact with Prometheus. Ascletis recruits Novartis veteran as CSO.
A third carcinogen was found in sartan drugs; China unveiled final rules for a Nasdaq-style board; Philippines preps to indict Sanofi officials.
Ascletis' stock price slips 44% in a month on HKEX; Zai Lab cans a dermatitis drug licensed from GSK; WuXi names CFO a co-CEO; and more.
Gilead's Epclusa Chinese nod comes just a few weeks after Merck’s Zepatier, and AbbVie's Mavyret is close behind.
Takeda plans major cuts after $62 billion Shire buyout; Ascletis files for HK IPO under new listing rules; AZ hands Seroquel rights to Luye Pharma.
Chinese pharmaceutical database PharmCube highlighted 16 possible blockbuster approvals in China in 2018.
In 2017's first issue of FiercePharmaAsia weekly wrap-up, Takeda spends $35 million on a GI deal, Ascletis is armed with $100 million in the country's HCV drug race, Sanofi's dengue vaccine promotional effort is halted by the Philippines' FDA, fire at Sun Pharma's API plant killed two, and more.
Hepatitis C is a big problem in China, and drugmakers are still waiting on approval for their next-gen treatments. Now, regulators are promising action--and Gilead Sciences is pressing the accelerator.
Calls are growing on China to speed up approvals for newer hepatitis C therapies as well as pricing access formulas.
At least one of China's estimated 30 million hepatitis C-infected patients found a way to make a bootleg cocktail of hepatitis C therapies by patching together ingredients via online shopping.